Sustiva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

efavirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Antivirali għal użu sistemiku

Therapeutic area:

Infezzjonijiet ta 'HIV

Therapeutic indications:

Sustiva huwa indikat fit-trattament ta 'kombinazzjoni antivirali ta' adulti, adolexxenti u tfal ta 'tlett snin u aktar b'infezzjoni ta' HIV-1 tal-bniedem-immunodefiċjenza-virus-1. Sustiva ma ġiex studjat biżżejjed fil-pazjenti f'fażi avvanzata tal-marda tal-HIV, u speċifikament pazjenti b'għadd CD4 < 50 ċellula/mm3, jew wara falliment ta ' protease inhibitor (PI) taħt kuri li kien fihom. Għalkemm il-reżistenza msallba ta 'efavirenz ma' PIs ma ġietx dokumentata, fil-preżent hemm biżżejjed informazzjoni fuq l-effikaċja tal-użu sussegwenti tal-PI tal-kura kombinata bbażata fuq wara li jkunu fallew il-kuri li fihom Sustiva.

Product summary:

Revision: 48

Authorization status:

Awtorizzat

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
NUMRU TA’ L-UE
ISEM
IVVINTAT
QAWWA
GĦAMLA
FARMAĊEWTIKA
MNEJN JINGĦATA
IL-PAKKETT
DAQS TAL-PAKKETT
EU/1/99/110/001
Sustiva
50 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
30 kapsula
EU/1/99/110/002
Sustiva
100 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
30 kapsula
EU/1/99/110/003
Sustiva
200 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
90 kapsula
EU/1/99/110/004
Sustiva
200 mg
Kapsula, iebsa
Użu orali
folja (alu/PVC)
42 kapsula
EU/1/99/110/008
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
flixkun (HDPE)
30 pillola
EU/1/99/110/009
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
folja (alu)
30 pillola
EU/1/99/110/010
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
folja (alu)
90 pillola
Prodott mediċinali li m’għadux awtorizzat
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
NUMRU TA’ L-UE
ISEM
IVVINTAT
QAWWA
GĦAMLA
FARMAĊEWTIKA
MNEJN JINGĦATA
IL-PAKKETT
DAQS TAL-PAKKETT
EU/1/99/110/001
Sustiva
50 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
30 kapsula
EU/1/99/110/002
Sustiva
100 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
30 kapsula
EU/1/99/110/003
Sustiva
200 mg
Kapsula, iebsa
Użu orali
flixkun (HDPE)
90 kapsula
EU/1/99/110/004
Sustiva
200 mg
Kapsula, iebsa
Użu orali
folja (alu/PVC)
42 kapsula
EU/1/99/110/008
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
flixkun (HDPE)
30 pillola
EU/1/99/110/009
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
folja (alu)
30 pillola
EU/1/99/110/010
Sustiva
600 mg
Pillola miksija b'rita
Użu orali
folja (alu)
90 pillola
Prodott mediċinali li m’għadux awtorizzat
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history